NRXS

Vorhandelsmarkt: 2.42

Neuraxis Inc (NRXS)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Neuraxis Inc Stock (NRXS) Company Profile

Neuraxis Inc

Healthcare (1173)

Biotechnology (661)

(812) 689-0791

11550 North Meridian Street, Suite 325, Carmel

Nächster Verdiensttermin

Neueste SEC-Einreichungen

NRXS's Discussions on Twitter

Vergleichen Sie NRXS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NRXS Neuraxis Inc	2.42	23.72M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	445.20	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	525.00	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	326.09	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	551.22	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	242.07	28.51B	3.81B	-644.79M	-669.77M	-6.24

Neuraxis Inc Aktie (NRXS) Neueste Nachrichten

Finanzdaten der Neuraxis Inc-Aktie (NRXS)

Es liegen keine Finanzdaten für Neuraxis Inc (NRXS) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Neuraxis Inc (NRXS)

Neuraxis Inc Stock (NRXS) Company Profile

Vergleichen Sie NRXS mit anderen Aktien

Neuraxis Inc Aktie (NRXS) Neueste Nachrichten

Neuraxis announces new medical policy with two health insurers - TipRanks

NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives - GlobeNewswire

NeurAxis, Inc. Expands Insurance Coverage for IB-Stim Therapy, Enhancing Access for Patients with Abdominal Pain - Nasdaq

NeurAxis (NASDAQ:NRXS) Now Covered by Analysts at Craig Hallum - Defense World

Neuraxis (NRXS) Initiated with Buy Rating by Craig-Hallum | NRXS Stock News - GuruFocus

Craig-Hallum initiates NeurAxis stock with buy rating on pediatric device - Investing.com India

Craig-Hallum bullish on Neuraxis, initiates with a Buy - TipRanks

Neuraxis, Inc. Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain in Ibs - MarketScreener

NeurAxis (NRXS) Gains Momentum with Key Guideline Inclusion | NR - GuruFocus

Neuraxis secures key academic society guidelines recommendation for FAP - TipRanks

NeurAxis Achieves Critical Milestone; Secures Key Academic - GlobeNewswire

Major Medical Guidelines Back NeurAxis $3B IBS Treatment for Children, Only FDA-Cleared Option - Stock Titan

47,094 Shares in NeurAxis, Inc. (NASDAQ:NRXS) Bought by Citadel Advisors LLC - Defense World

NeurAxis, Inc. Approves Key Proposals at Annual Meeting - TipRanks

NeurAxis, Inc. Releases Investor Presentation - TipRanks

NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 - The Manila Times

Biotech Alert: Searches spiking for these stocks today - TipRanks

NeurAxis Closes $5 Million Direct Offering - marketscreener.com

NeurAxis, Inc. Completes $5 Million Registered Direct Offering to Support Growth of IB-Stim Therapy - Nasdaq

NeurAxis Announces Closing of $5.0 Million Registered Direct Offering - GlobeNewswire

NeurAxis announces USD 5M registered direct offering - Medical Buyer

NeurAxis, Inc. Announces $5 Million Stock Offering - TipRanks

Form 424B5 Neuraxis, INC - StreetInsider

SEC Form 424B5 filed by Neuraxis Inc. - Quantisnow

Neuraxis settles lawsuit with $750,000 agreement By Investing.com - Investing.com South Africa

NeurAxis, Inc. Receives $1 Million from Warrant Exercises - TipRanks

Neuraxis settles lawsuit with $750,000 agreement - Investing.com

NeurAxis slides 21%, raises $5M via stock - MSN

Edible Garden's Sports Nutrition Launch On Amazon Sends Stocks Climbing - Finimize

NeurAxis To Sell About 1.5 Mln Stock At $3.25/shr; Stock Plunges In Pre-market - Nasdaq

NeurAxis (NRXS) Announces $5M Direct Stock Offering - GuruFocus

NeurAxis Launches $5 Million Direct Offering - marketscreener.com

NeurAxis (NRXS) Announces Direct Stock Offering to Raise $5 Mill - GuruFocus

Neuraxis prices 1.54M shares at $3.25 in registered direct offering - TipRanks

NeurAxis Announces $5.0 Million Registered Direct Offering - The Manila Times

NeurAxis Awarded First Ever FDA Clearance for the Treatment - GlobeNewswire

NeurAxis Stock Soars on Groundbreaking FDA Clearance for Pediatric Treatment - Wall Street Pit

Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings - Benzinga

Wall Street’s Dramatic Shifts Uncover Unexpected Winners and Losers—What’s Behind Today’s Wild Market Moves? - macholevante.com

NeurAxis Shares Climb After FDA Clearance of IB-Stim for Treating Pediatric Dyspepsia - marketscreener.com

NeurAxis (NRXS) Stock Surges Following Breakthrough FDA Clearance - Stocks Telegraph

Neuraxis, Inc. Common Stock (NYSE:NRXS) Stock Quote - FinancialContent

Nasdaq Falls 100 Points; Home Depot Sales Top Views - Benzinga

NRXS stock touches 52-week high of $5.67 amid market fluctuations - Investing.com

NeurAxis, Inc. Receives First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia and Associated Nausea Symptoms - marketscreener.com

Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews

NeurAxis (NRXS) Gains FDA Clearance for Expanded Use of IB-Stim - GuruFocus

Finanzdaten der Neuraxis Inc-Aktie (NRXS)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie NRXS